These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 32575112)
1. Direct oral anticoagulants and cancer-associated VTE: good for all, or just some? Carrier M; Wang TF Blood; 2020 Aug; 136(6):669-673. PubMed ID: 32575112 [TBL] [Abstract][Full Text] [Related]
2. Anticoagulation for COVID-19 Patients: A Bird's-Eye View. Kreidieh F; Temraz S Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937 [TBL] [Abstract][Full Text] [Related]
3. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194 [TBL] [Abstract][Full Text] [Related]
4. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer. Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316 [TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Mulder FI; Bosch FTM; Young AM; Marshall A; McBane RD; Zemla TJ; Carrier M; Kamphuisen PW; Bossuyt PMM; Büller HR; Weitz JI; Middeldorp S; van Es N Blood; 2020 Sep; 136(12):1433-1441. PubMed ID: 32396939 [TBL] [Abstract][Full Text] [Related]
6. Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study. Campello E; Spiezia L; Simion C; Tormene D; Camporese G; Dalla Valle F; Poretto A; Bulato C; Gavasso S; Radu CM; Simioni P J Am Heart Assoc; 2020 Dec; 9(23):e018917. PubMed ID: 33222589 [TBL] [Abstract][Full Text] [Related]
7. [Factor Xa inhibitors - equivalent to low molecular weight heparin for the treatment of cancer-associated venous thromboembolism]. Magnusson P; Mattsson G Lakartidningen; 2021 Apr; 118():. PubMed ID: 33836092 [TBL] [Abstract][Full Text] [Related]
8. Cancer is not a single disease: is it safe to extrapolate evidence from trials of direct oral anticoagulants in cancer-associated venous thromboembolism to patients with haematological malignancies? Buka RJ; Chandra D; Sutton DJ Br J Haematol; 2021 Apr; 193(1):194-197. PubMed ID: 33618429 [No Abstract] [Full Text] [Related]
9. Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials. Murphy AC; Koshy AN; Farouque O; Yeo B; Raman J; Kearney L; Yudi MB Heart Lung Circ; 2022 May; 31(5):716-725. PubMed ID: 34896013 [TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis. Lu X; Lin J BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update. Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760 [TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient). Pernod G; Joly M; Sonnet B J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants. Carrier M; Soff G; Le Gal G Cancer Treat Res; 2019; 179():103-115. PubMed ID: 31317483 [TBL] [Abstract][Full Text] [Related]
15. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis. Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142 [TBL] [Abstract][Full Text] [Related]
16. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261 [TBL] [Abstract][Full Text] [Related]
17. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. Kaatz S; Ahmad D; Spyropoulos AC; Schulman S; J Thromb Haemost; 2015 Nov; 13(11):2119-26. PubMed ID: 26764429 [No Abstract] [Full Text] [Related]
18. A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK. Cohen AT; Benson G; Bradbury CA; Choudhuri S; Hutchinson Jones N; Maraveyas A; Venugopal B; Young AM; Chapman C; McIntyre S; Burney D; Pollock KG; Morgan AR; Gabb PD; Alikhan R Curr Med Res Opin; 2023 Mar; 39(3):483-495. PubMed ID: 36629478 [TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer. Lee JH; Oh YM; Lee SD; Lee JS J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482 [TBL] [Abstract][Full Text] [Related]
20. Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study. Sevestre MA; Belizna C; Durant C; Bosson JL; Vedrine L; Cajfinger F; Debourdeau P; Farge D; J Mal Vasc; 2014 May; 39(3):161-8. PubMed ID: 24746736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]